ArticleBMC medical research methodology2025
HILAMA: High-dimensional multi-omics mediation analysis with latent confounding.
Article in BMC medical research methodology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Are we ready for causal discovery in biological systems using deep learning?Briefings in bioinformatics · 2026Article
- Hippocampal mediation in the lipid-Alzheimer's disease pathway: A high-dimensional mediation analysis stratified byAlzheimer's & dementia (New York, N. Y.)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundThe increasingly available multi-omics datasets have posed both new opportunities and challenges to the development of quantitative methods for discovering novel mechanisms in biomedical research. One natural approach to analyzing such datasets is mediation analysis originated from the causal inference literature. Mediation analysis can help unravel the mechanisms through which exposure(s) exert the effect on outcome(s). However, existing methods fail to consider the case where (1) both exposures and mediators are potentially high-dimensional and (2) it is very likely that some important confounding variables are unmeasured or latent; both issues are quite common in practice. To the best of our knowledge, however, no methods have been developed to address these challenges with statistical guarantees.
methodsIn this article, we propose a new method for HIgh-dimensional LAtent-confounding Mediation Analysis (HILAMA) that considers both high-dimensional exposures and mediators, as well as the possible existence of latent confounding variables. HILAMA employs the Decorrelating & Debiasing method to estimate the individual effects of exposures and mediators on the outcome. A column-wise regression strategy with parallel computing is considered to efficiently estimate the exposure-mediator effect matrix. HILAMA then applies the MinScreen procedure to eliminate non-significant pairs, and the Joint-Significance Testing (JST) method to compute p-values for the retained pairs, controlling the False Discovery Rate (FDR) using the Benjamini-Hochberg (BH) procedure.
resultsThe proposed method is evaluated through extensive simulation experiments, demonstrating its improved stability in FDR control and superior power in finite sample size compared to existing competitive methods. Furthermore, our method is applied to the proteomics-radiomics data from ADNI, identifying some key proteins and brain regions related to Alzheimer’s disease. These empirical results demonstrate that HILAMA can effectively control FDR and provide valid statistical inference for high dimensional mediation analysis with latent confounding variables under certain assumptions.
conclusionsHILAMA can effectively control FDR and provide valid statistical inference for high dimensional mediation analysis with latent confounding variables under certain assumptions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.